COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

Issuer:
Gilles R. Gagnon
President & CEO
+1 (780) 421-4555
E: ggagnon@ceapro.com Read More

Ads Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute
Dorel reports US$21.9M Q3 loss compared with US$10.4M loss a year ago, revenue down
Ford agrees to pay up to $165 million penalty to US government for moving too slowly on recall

Vanguard Investments Canada Announces Estimated 2024 Year-End Distributions for Vanguard Mutual Funds
ACTG Presents Two Studies Providing Insights Into TB Treatment at Union Conference on Lung Health